The estimated Net Worth of Eric Dobmeier is at least $17.9 Milión dollars as of 10 November 2023. Mr. Dobmeier owns over 446,825 units of Atara Biotherapeutics Inc stock worth over $4,681,231 and over the last 21 years he sold ATRA stock worth over $12,910,302. In addition, he makes $327,492 as Independent Director at Atara Biotherapeutics Inc.
Eric has made over 54 trades of the Atara Biotherapeutics Inc stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 446,825 units of ATRA stock worth $102,770 on 10 November 2023.
The largest trade he's ever made was buying 446,825 units of Atara Biotherapeutics Inc stock on 10 November 2023 worth over $102,770. On average, Eric trades about 14,563 units every 42 days since 2003. As of 10 November 2023 he still owns at least 563,325 units of Atara Biotherapeutics Inc stock.
You can see the complete history of Mr. Dobmeier stock trades at the bottom of the page.
Eric L. Dobmeier serves as Independent Director of the Company since March 2015. Mr. Dobmeier has served as President and Chief Executive Officer of Chinook Therapeutics, Inc., a biotechnology company, since April 2019. From January 2018 to June 2018, Mr. Dobmeier was President and Chief Executive Officer of Silverback Therapeutics, Inc., a biotechnology company. Previously, he was at Seattle Genetics, Inc., a biotechnology company, where he held positions of increasing responsibility for more than 15 years, most recently as Chief Operating Officer from June 2011 to December 2017. Prior to joining Seattle Genetics, Mr. Dobmeier was an attorney with the law firms of Venture Law Group and Heller Ehrman LLP, where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Mr. Dobmeier served on the board of directors of Stemline Therapeutics from 2012 to 2018, and served on the board of directors of Versartis from 2017 to 2018. He currently serves on the board of directors of Adaptive Biotechnologies, where he has served as a director since 2016. Mr. Dobmeier received a J.D. from the University of California, Berkeley School of Law and an A.B. in History from Princeton University.
As the Independent Director of Atara Biotherapeutics Inc, the total compensation of Eric Dobmeier at Atara Biotherapeutics Inc is $327,492. There are 9 executives at Atara Biotherapeutics Inc getting paid more, with Pascal Touchon having the highest compensation of $6,637,310.
Eric Dobmeier is 51, he's been the Independent Director of Atara Biotherapeutics Inc since 2015. There are 8 older and 7 younger executives at Atara Biotherapeutics Inc. The oldest executive at Atara Biotherapeutics Inc is Roy Baynes, 65, who is the Independent Director.
Eric's mailing address filed with the SEC is C/O ATARA BIOTHERAPEUTICS, INC., 2380 CONEJO SPECTRUM ST, SUITE 200, THOUSAND OAKS, CA, 91320.
Over the last 10 years, insiders at Atara Biotherapeutics Inc have traded over $58,305,463 worth of Atara Biotherapeutics Inc stock and bought 1,293,860 units worth $5,821,259 . The most active insiders traders include Joel S Marcus, Eric Dobmeier a Ronald C Jr Renaud. On average, Atara Biotherapeutics Inc executives and independent directors trade stock every 9 days with the average trade being worth of $99,047. The most recent stock trade was executed by Pascal Touchon on 16 August 2024, trading 3,038 units of ATRA stock currently worth $20,142.
we launched atara biotherapeutics in august 2012 to help patients combat cancer, kidney disease and other illnesses. our research is based on groundbreaking discoveries regarding the ability of activin, myostatin and other growth factors to change the course of disease progression. our goal is to help patients such as atara ciechanover, our company’s namesake, who suffered from cancer before passing away in 2012. we aim to empower patients to fight their illnesses with better treatment options. atara biotherapeutics is developing several innovative product candidates, including pinta 745, stm 434 and ata 842, and is collaborating with memorial sloan kettering cancer center (msk) in the development of three t-cell product candidates: epstein-barr virus (ebv)-targeted cytotoxic t lymphocytes (ctls), cytomegalovirus (cmv)-targeted ctls, and wilms tumor 1 (wt1)-targeted ctls. each product candidate is designed to address the underlying mechanisms of disease to treat conditions which have
Atara Biotherapeutics Inc executives and other stock owners filed with the SEC include: